Skip to main
ARGX

argenx (ARGX) Stock Forecast & Price Target

argenx (ARGX) Analyst Ratings

Based on 18 analyst ratings
Buy
Strong Buy 44%
Buy 50%
Hold 6%
Sell 0%
Strong Sell 0%

Bulls say

argenx is a promising investment opportunity due to its strong financial situation, with the recent FDA approvals of Vyvgart and Vyvgart Hytrulo for multiple autoimmune diseases, as well as ongoing clinical trials for multiple indications. The company's innovative approach to targeting antibody-driven immune disorders, as shown by its pipeline of potential treatments, also bodes well for its future success. Furthermore, the positive data from the Phase 3 ALKIVIA trial for Vyvgart in myositis and the potential for a label expansion to include DM only add to the company's promising outlook.

Bears say

argenx is a Dutch biopharmaceutical company with a strong focus on research and development of antibody-based treatments for rare autoimmune diseases. Despite recent FDA approvals for its lead product Vyvgart/efgartigimod, there is potential for market competition with new products in development by other companies. Additionally, the success of ARGX is heavily reliant on the outcomes of clinical trials and regulatory approvals, and any setbacks could negatively impact its revenue growth and stock price. There are also potential risks in securing and maintaining patent protection, as well as potential pricing pressure. Overall, the company's stock may face challenges in the future and its current valuation may not fully reflect these risks.

argenx (ARGX) has been analyzed by 18 analysts, with a consensus rating of Buy. 44% of analysts recommend a Strong Buy, 50% recommend Buy, 6% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of argenx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About argenx (ARGX) Forecast

Analysts have given argenx (ARGX) a Buy based on their latest research and market trends.

According to 18 analysts, argenx (ARGX) has a Buy consensus rating as of Sep 14, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $1,166.89, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $1,166.89, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

argenx (ARGX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.